Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

GC-072: A Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens.

Shearer JD, Saylor ML, Butler CM, Treston AM, Heine HS, Chirakul S, Schweizer HP, Louie A, Drusano GL, Zumbrun SD, Warfield KL.

Antimicrob Agents Chemother. 2019 Sep 23. pii: AAC.00834-19. doi: 10.1128/AAC.00834-19. [Epub ahead of print]

2.

The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus Macaques.

Grossman TH, Anderson MS, Drabek L, Gooldy M, Heine HS, Henning LN, Lin W, Newman JV, Nevarez R, Siefkas-Patterson K, Radcliff AK, Sutcliffe JA.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01103-17. doi: 10.1128/AAC.01103-17. Print 2017 Oct.

3.

Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model.

Heine HS, Shadomy SV, Boyer AE, Chuvala L, Riggins R, Kesterson A, Myrick J, Craig J, Candela MG, Barr JR, Hendricks K, Bower WA, Walke H, Drusano GL.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00788-17. doi: 10.1128/AAC.00788-17. Print 2017 Sep.

4.

In Vitro Antibiotic Susceptibilities of Francisella tularensis Determined by Broth Microdilution following CLSI Methods.

Heine HS, Miller L, Halasohoris S, Purcell BK.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00612-17. doi: 10.1128/AAC.00612-17. Print 2017 Sep.

5.

The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques.

Grossman TH, Anderson MS, Christ D, Gooldy M, Henning LN, Heine HS, Kindt MV, Lin W, Siefkas-Patterson K, Radcliff AK, Tam VH, Sutcliffe JA.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00448-17. doi: 10.1128/AAC.00448-17. Print 2017 Aug.

6.

Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice.

Heine HS, Chuvala L, Riggins R, Cirz R, Cass R, Louie A, Drusano GL.

Antimicrob Agents Chemother. 2016 Jan 11;60(3):1834-40. doi: 10.1128/AAC.02887-15.

7.

In vitro antibiotic susceptibilities of Yersinia pestis determined by broth microdilution following CLSI methods.

Heine HS, Hershfield J, Marchand C, Miller L, Halasohoris S, Purcell BK, Worsham PL.

Antimicrob Agents Chemother. 2015 Apr;59(4):1919-21. doi: 10.1128/AAC.04548-14. Epub 2015 Jan 12.

8.

Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.

Heine HS, Louie A, Adamovicz JJ, Amemiya K, Fast RL, Miller L, Opal SM, Palardy J, Parejo NA, Sörgel F, Kinzig-Schippers M, Drusano GL.

Antimicrob Agents Chemother. 2014 Jun;58(6):3276-84. doi: 10.1128/AAC.02420-14. Epub 2014 Mar 31.

9.

Natural history of Yersinia pestis pneumonia in aerosol-challenged BALB/c mice.

Heine HS, Chuvala L, Riggins R, Hurteau G, Cirz R, Cass R, Louie A, Drusano GL.

Antimicrob Agents Chemother. 2013 May;57(5):2010-5. doi: 10.1128/AAC.02504-12. Epub 2013 Feb 12.

10.

Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.

Louie A, VanScoy BD, Brown DL, Kulawy RW, Heine HS, Drusano GL.

Antimicrob Agents Chemother. 2012 Mar;56(3):1229-39. doi: 10.1128/AAC.01109-10. Epub 2011 Dec 12.

11.

Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.

Louie A, Vanscoy BD, Heine HS 3rd, Liu W, Abshire T, Holman K, Kulawy R, Brown DL, Drusano GL.

Antimicrob Agents Chemother. 2012 Jan;56(1):513-7. doi: 10.1128/AAC.05724-11. Epub 2011 Nov 7.

12.

Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model.

Louie A, Vanscoy B, Liu W, Kulawy R, Brown D, Heine HS, Drusano GL.

Antimicrob Agents Chemother. 2011 Jun;55(6):2623-8. doi: 10.1128/AAC.01374-10. Epub 2011 Apr 12.

13.

Comparison of Etest method with reference broth microdilution method for antimicrobial susceptibility testing of Yersinia pestis.

Lonsway DR, Urich SK, Heine HS, McAllister SK, Banerjee SN, Schriefer ME, Patel JB.

J Clin Microbiol. 2011 May;49(5):1956-60. doi: 10.1128/JCM.00142-11. Epub 2011 Mar 16.

14.

Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.

Louie A, Heine HS, VanScoy B, Eichas A, Files K, Fikes S, Brown DL, Liu W, Kinzig-Schippers M, Sörgel F, Drusano GL.

Antimicrob Agents Chemother. 2011 Feb;55(2):822-30. doi: 10.1128/AAC.00818-10. Epub 2010 Nov 29.

15.

Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.

Heine HS, Bassett J, Miller L, Purcell BK, Byrne WR.

Antimicrob Agents Chemother. 2010 Oct;54(10):4471-3. doi: 10.1128/AAC.00210-10. Epub 2010 Jul 19.

16.

Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.

Gill SC, Rubino CM, Bassett J, Miller L, Ambrose PG, Bhavnani SM, Beaudry A, Li J, Stone KC, Critchley I, Janjic N, Heine HS.

Antimicrob Agents Chemother. 2010 May;54(5):1678-83. doi: 10.1128/AAC.00737-08. Epub 2010 Feb 9.

17.

Identification of ciprofloxacin resistance by SimpleProbe, High Resolution Melt and Pyrosequencing nucleic acid analysis in biothreat agents: Bacillus anthracis, Yersinia pestis and Francisella tularensis.

Loveless BM, Yermakova A, Christensen DR, Kondig JP, Heine HS 3rd, Wasieloski LP, Kulesh DA.

Mol Cell Probes. 2010 Jun;24(3):154-60. doi: 10.1016/j.mcp.2010.01.003. Epub 2010 Jan 25.

PMID:
20100564
18.

Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.

Heine HS, Purcell BK, Bassett J, Miller L, Goldstein BP.

Antimicrob Agents Chemother. 2010 Mar;54(3):991-6. doi: 10.1128/AAC.00820-09. Epub 2010 Jan 4.

19.

Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.

Drusano GL, Okusanya OO, Okusanya AO, van Scoy B, Brown DL, Fregeau C, Kulawy R, Kinzig M, Sörgel F, Heine HS, Louie A.

Antimicrob Agents Chemother. 2009 Nov;53(11):4718-25. doi: 10.1128/AAC.00802-09. Epub 2009 Aug 17.

20.

Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?

Drusano GL, Okusanya OO, Okusanya A, Van Scoy B, Brown DL, Kulawy R, Sörgel F, Heine HS, Louie A.

Antimicrob Agents Chemother. 2008 Nov;52(11):3973-9. doi: 10.1128/AAC.00453-08. Epub 2008 Aug 25.

21.

Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.

Heine HS, Bassett J, Miller L, Bassett A, Ivins BE, Lehoux D, Arhin FF, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2008 Sep;52(9):3350-7. doi: 10.1128/AAC.00360-08. Epub 2008 Jul 7.

22.

Application of carbohydrate microarray technology for the detection of Burkholderia pseudomallei, Bacillus anthracis and Francisella tularensis antibodies.

Parthasarathy N, Saksena R, Kováč P, Deshazer D, Peacock SJ, Wuthiekanun V, Heine HS, Friedlander AM, Cote CK, Welkos SL, Adamovicz JJ, Bavari S, Waag DM.

Carbohydr Res. 2008 Nov 3;343(16):2783-8. doi: 10.1016/j.carres.2008.05.021. Epub 2008 Jun 14.

PMID:
18558401
23.

Petrobactin is produced by both pathogenic and non-pathogenic isolates of the Bacillus cereus group of bacteria.

Koppisch AT, Dhungana S, Hill KK, Boukhalfa H, Heine HS, Colip LA, Romero RB, Shou Y, Ticknor LO, Marrone BL, Hersman LE, Iyer S, Ruggiero CE.

Biometals. 2008 Oct;21(5):581-9. doi: 10.1007/s10534-008-9144-9. Epub 2008 May 6.

PMID:
18459058
24.

Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.

Louie A, Heine HS, Kim K, Brown DL, VanScoy B, Liu W, Kinzig-Schippers M, Sörgel F, Drusano GL.

Antimicrob Agents Chemother. 2008 Jul;52(7):2486-96. doi: 10.1128/AAC.01439-07. Epub 2008 May 5.

25.

Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.

Ambrose PG, Forrest A, Craig WA, Rubino CM, Bhavnani SM, Drusano GL, Heine HS.

Antimicrob Agents Chemother. 2007 Dec;51(12):4351-5. Epub 2007 Sep 17.

26.

Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.

Heine HS, Louie A, Sorgel F, Bassett J, Miller L, Sullivan LJ, Kinzig-Schippers M, Drusano GL.

J Infect Dis. 2007 Sep 1;196(5):782-7. Epub 2007 Jul 19.

PMID:
17674322
27.

Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.

Heine HS, Bassett J, Miller L, Hartings JM, Ivins BE, Pitt ML, Fritz D, Norris SL, Byrne WR.

Antimicrob Agents Chemother. 2007 Apr;51(4):1373-9. Epub 2007 Feb 12.

28.

Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax.

Vietri NJ, Purcell BK, Lawler JV, Leffel EK, Rico P, Gamble CS, Twenhafel NA, Ivins BE, Heine HS, Sheeler R, Wright ME, Friedlander AM.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7813-6. Epub 2006 May 3.

29.
30.

Antimycobacterial activity of cerulenin and its effects on lipid biosynthesis.

Parrish NM, Kuhajda FP, Heine HS, Bishai WR, Dick JD.

J Antimicrob Chemother. 1999 Feb;43(2):219-26.

PMID:
11252327
31.

Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer.

Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR, Kuhajda FP.

Cancer Res. 1996 Mar 15;56(6):1189-93.

32.

Enhancement of epoxide hydrolase activity in hepatic microsomes of mice given heterocyclic compounds.

Heine HS, Stoskopf MK, Thompson DC, Cha YN.

Chem Biol Interact. 1986 Sep;59(2):219-30.

PMID:
3769053
33.

Adenosine triphosphate content of Mycobacterium leprae isolated from armadillo tissue by Percoll buoyant density centrifugation.

Kvach JT, Neubert TA, Palomino JC, Heine HS.

Int J Lepr Other Mycobact Dis. 1986 Mar;54(1):1-10.

PMID:
3519794
35.
37.

Differential effects of dietary and intraperitoneal administration of antioxidants on the activities of several hepatic enzymes of mice.

Cha YN, Heine HS, Moldeus P.

Drug Metab Dispos. 1982 Jul-Aug;10(4):434-5. No abstract available.

PMID:
6126347
38.

Effect of unisexual Schistosoma mansoni infections on hepatic drug metabolism of mice.

Cha YN, Heine HS, Bueding E.

Am J Trop Med Hyg. 1980 Mar;29(2):227-33.

PMID:
7369443
39.

Effect of Schistosoma mansoni infection on hepatic drug-metabolizing capacity of athymic nude mice.

Cha YN, Byram JE, Heine HS, Bueding E.

Am J Trop Med Hyg. 1980 Mar;29(2):234-8.

PMID:
6966141
40.

Elevation of extrahepatic glutathione S-transferase and epoxide hydratase activities by 2(3)-tert-butyl-4-hydroxyanisole.

Benson AM, Cha YN, Bueding E, Heine HS, Talalay P.

Cancer Res. 1979 Aug;39(8):2971-7. No abstract available.

Supplemental Content

Loading ...
Support Center